SS262 Insomnia Treatment Phase 1 Trial Terminated Early, Shift to New Pipeline Development
Phase 1 clinical trial of SS262 for insomnia (26 healthy male subjects) terminated early
Decision based on market environment and R&D portfolio strategy, shifting to next-generation pipeline based on sleep-inducing patch
Existing research outcomes (formulation technology, patents) to be utilized for new pipeline
Trial ended approximately 2 years after approval (approved May 2024, early termination reported May 2026)
KOSDAQ Filing Information
Filing: Major Management Issue Related to Investment Decision (Voluntary Withdrawal of Clinical Trial Plan, etc.) (Early Termination of Phase 1 Clinical Trial of SS262 for Short-Term Treatment of Insomnia Patients)